Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004138
Status:
COMPLETED
Last Update Posted:
2016-07-13
First Post:
1999-12-10
Brief Title:
Positron Emission Tomography for Detecting Non-small Cell Lung Cancer
Sponsor:
Alliance for Clinical Trials in Oncology
Organization:
Alliance for Clinical Trials in Oncology
Study Overview
Official Title:
The Utility of Positron Emission Tomography PET in Staging of Patients With Potentially Operable Non-Small Cell Lung Carcinoma
Status:
COMPLETED
Status Verified Date:
2016-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Imaging procedures such as positron emission tomography PET may improve the ability to detect the extent of non-small cell lung cancer
PURPOSE Diagnostic trial to study the effectiveness of PET for detecting lesions in patients who have newly diagnosed stage I stage II or stage IIIA non-small cell lung cancer
PURPOSE Diagnostic trial to study the effectiveness of PET for detecting lesions in patients who have newly diagnosed stage I stage II or stage IIIA non-small cell lung cancer
Detailed Description:
OBJECTIVES
Primary Objective To ascertain whether FDG-PET scanning can detect lesions that would preclude pulmonary resection in patients found to be surgical candidates by standard imaging procedures
Secondary Objectives To use the data collected to generate hypotheses to be used in future studies such as which types of previously undetected lesions FDG-PET is best able to identify
Patients receive fludeoxyglucose F 18 FDG IV followed 45-60 minutes later by positron emission tomography PET imaging Confirmatory studies such as biopsy fine needle aspiration or other imaging studies are then conducted to confirm the PET findings
Patients with no mediastinal nodal or distant metastases identified by FDG-PET scan may undergo thoracotomy and pulmonary resection within 1 month of evaluation
Patients are followed at 5-6 months after surgery
Primary Objective To ascertain whether FDG-PET scanning can detect lesions that would preclude pulmonary resection in patients found to be surgical candidates by standard imaging procedures
Secondary Objectives To use the data collected to generate hypotheses to be used in future studies such as which types of previously undetected lesions FDG-PET is best able to identify
Patients receive fludeoxyglucose F 18 FDG IV followed 45-60 minutes later by positron emission tomography PET imaging Confirmatory studies such as biopsy fine needle aspiration or other imaging studies are then conducted to confirm the PET findings
Patients with no mediastinal nodal or distant metastases identified by FDG-PET scan may undergo thoracotomy and pulmonary resection within 1 month of evaluation
Patients are followed at 5-6 months after surgery
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000067368 | REGISTRY | NCI Physician Data Query | None |